Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CA7 | P43166 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.59 |
| ▸ | HPGDS | O60760 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23117231 | 0.89 | CA1 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16921588 | 0.89 | CA12 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3459740 | 0.89 | CA12 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16661301 | 0.88 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16787530 | 0.86 | HPGDS (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL27517664 | 0.82 | CA12 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8239580 | 0.82 | CA9 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5707733 | 0.81 | PPARG (0.47) | GSK3BPPARAKDM4EALDH1A1HSD17B10 | |
| SCHEMBL12248740 | 0.78 | HPGDS (0.47) | HPGDSGSK3BALDH1A1SMN1; SMN2POLB | |
| SCHEMBL27861005 | 0.78 | CA12 (0.57) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308636-B2 | Aromatic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-04 | — | — | US | disclosed |
| EP-2862856-B1 | IMIDAZOLE AND TRIAZOLE COMPOUNDS AS DGAT-1 INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2018-08-01 | — | — | EP | disclosed |
| EP-2266958-B1 | Antiviral agent | SHIONOGI & CO (JP) | 2017-03-15 | — | — | EP | disclosed |
| EP-2266958-B1 | Antiviral agent | SHIONOGI & CO (JP) | 2017-03-15 | — | — | EP | disclosed |
| US-20170066754-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
| US-20170066754-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
| US-20170050950-A1 | AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-23 | — | — | US | disclosed |
| US-9572813-B2 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2017-02-21 | — | — | US | disclosed |
| US-9572813-B2 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2017-02-21 | — | — | US | disclosed |
| US-9546155-B2 | Aromatic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-17 | — | — | US | disclosed |
| US-20010039275-A1 | Use of 2,4-diaminothiazole derivatives | NOVO NORDISK A/S (DK) | 2001-11-08 | — | — | US | disclosed |
| WO-2001056567-A1 | 2,4-DIAMINOTHIAZOLE DERIVATIVES AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 (GSK-3) INHIBITORS | NOVO NORDISK A/S (DK) | 2001-08-09 | — | — | WO | disclosed |
| EP-0904274-A4 | FARNESYL TRANSFERASE INHIBITORS | BIOMEASURE INC (US) | 1999-12-29 | — | — | EP | disclosed |
| US-5958950-A | CARDIOVASCULAR DISORDERS | WARNER-LAMBERT COMPANY (US) | 1999-09-28 | — | — | US | disclosed |
| EP-0904274-A1 | FARNESYL TRANSFERASE INHIBITORS | Biomeasure Incorporated (US) | 1999-03-31 | — | — | EP | disclosed |
| EP-0564924-B1 | 2-Oxoethyl derivatives as immunosuppressants | BAYER AG (US) | 1998-09-09 | — | — | EP | disclosed |
| US-5686424-A | FOR TREATING INFLAMMATION | MILES INC. (US) | 1997-11-11 | — | — | US | disclosed |
| WO-1997030053-A9 | FARNESYL TRANSFERASE INHIBITORS | — | 1997-10-30 | — | — | WO | disclosed |
| WO-1997030053-A1 | FARNESYL TRANSFERASE INHIBITORS | BIOMEASURE INCORPORATED (US) | 1997-08-21 | — | — | WO | disclosed |
| WO-1997012615-A1 | BENZIMIDAZOLE DERIVATIVES AS 15-LO INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1997-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308636-B2 | Aromatic heterocyclic compound | GPR119, NR0B1, BET1 | CA12 2718/4885CA1 3248/4885CA2 1729/4885 |
| US-20010039275-A1 | Use of 2,4-diaminothiazole derivatives | GSK3A, GSK3B, GSKIP | CA12 3671/4885CA1 2506/4885CA2 2632/4885 |
| US-20170066754-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | CA12 4630/4885CA1 4422/4885CA2 4439/4885 |
| US-20170050950-A1 | AROMATIC HETEROCYCLIC COMPOUND | GPR119, NR0B1, BET1 | CA12 2718/4885CA1 3248/4885CA2 1729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.